Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis

Table 1 Basic characteristics of included literature

Ref.	Country	Drug	Tumor type	Gender	Study type	Patients number	Cutoff values	Outcome measures
Imai et al[22], 2015	Japan	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	40	L3 SMI: 39.2 cm2/m2	OS
Naganuma et al[14], 2017	Japan	Sorafenib	Hepatocellular carcinoma	Male	Retro	51	L3 SMI: 43 cm2/m2	OS
Saeki et al[21], 2018	Japan	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	100	L3 SMI: male, 42 cm2/m2, female, 38 cm2/m2	OS
Takada et al[15], 2018	Japan	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	146	L3 SMI: male, 42 cm2/m2, female, 38 cm2/m2	OS
Labeur et al[19], 2019	The Netherlands	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	278	L3 SMI: male, 49.5 cm2/m2, female, 39.8 cm2/m2	OS
Uojima et al[18], 2020	Japan	Lenvatinib	Hepatocellular carcinoma	Female + male	Retro	100	L3 SMI: male, 42 cm2/m2, female, 38 cm2/m2	OS
Saeki et al[23], 2021	Japan	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	356	L3 SMI: male, 45 cm2/m2, female, < 38 cm2/m2	OS
Wu et al[16], 2021	Taipei, Taiwan	Sorafenib	Hepatocellular carcinoma	Male	Retro	120	L3 SMI: 39.1 cm2/m2	OS
Nishikawa et al[24], 2017	Japan	Sorafenib	Hepatocellular carcinoma	Female + male	Retro	232	L3 SMI: male, 36.2 cm2/m2, female, 29.6 cm2/m2	OS

SMI: Skeletal muscle index; OS: Overall survival.